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Project Purpose & Critical Questions
EMGT 520- December-2002
What are the competitive strategies of AMGEN ? 
What role does strategic planning play at AMGEN? How useful is it? 
How  AMGEN managing  science and technology to become a  leader
in the biotech industry?
AMGEN
1980- first inception of Applied Molecular Genetics
1983- initiated PO
1987- built commercial R&D facility
1988- launched its first product, Novantrone (Cancer)
1989- launch its second product, Epogen (renal failure anemia)
established operations in Europe
1991- launch its third product, Neupogen (Neutropenia)
established operations in Australia and Canada
1992- established operations in Hong Kong and Japan
1994- launched Thioplex (Cancer)
1998- launched Enbrel (Rhuematoid Arthritis)
2001- launched Keneret (Rhuematoid Arthritis) and Aranesp 
(renal failure anemia)
2002- launched Neulasta (Neutropenia)
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Strategy Formulation
“Competitive Strategy"a combination of the ends 
(goals) for which the firm is striving and the 
means (policies) by which it is seeking to get 
there.“ (Porter,1980)
Competitive strategy is required to successfully 
compete in a given industry.
“Strategy is a process for setting the direction of the
busines future” (F.Betz, 1998)
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Human Resource  (Talented Scientists)
Strategic Partnerships/Alliances




Government regulations (FDA) and 
Healthcare policies
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Corporate Goals & Values
Goals
Launch a stream of products for improving dramatically patient`s lives
Create an environment where the best people choose to work
Deliver superior shareholder returns compared to our industry peer group
Be a good corporate citizen in communities where our staff live and work
Values
Be Science-based company
Compete intensely and win
Create value for patients,staff and stockholders
Be ethical
Trust and respect each other
Work in teams
Ensure quality
Collaborate communicate and build consensus
Management Preferences









• Partnerships and Knowledge













•Facilities and R&D Facilities

































































• 87% of Amgen Revenue
• Still sales increment
Novatrone
• High R&D costs
• Low Sales
Thioplex
• Recovered R&D costs
• Medium Sales
• Expected Higher Revenue
Infergen
• Not profitable products
• High Sales Forecast
Strategic Alliances
Announce 10 years research partnership with MIT in 1994
Acquired Kenetix in 2000 and Immunex in 2002
Source:Cornell Equity Research/Cornell University
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Strategic Partnerships & Alliances
Based on January 2001 Wood Mckenzie Company Reviews for AMGEN
Product Sales of 3202.2m (88.2.%), YoY increase of 5.2%
Corporate Partnership Revenues of 246.2m (6.8%), YoY increase of 52.5%
Royalty Income of 181.0m (5%), YoY increase of 33.2%
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Strengths
High Level R&D spending (average, 26.4% of revenues)
Well-established Epogen, Neupogen, and  Infergen products.
Steady Cash Flow
Established procedures and strong experience for licensing.
Strong sales force in the area of oncology
Excellent “brand equity”. AMGEN products have an excellent reputation, and are 
well respected by patients, and more importantly, physicians (prescribers). 
AMGEN has collaborative arrangements with about 200 colleges and universities.





The company does not have an extensive global distribution system relative to most 
major pharmaceutical firms (e.g. Pfizer).  
The lack of  product diversification makes AMGEN more vulnerable to its competitors 
and to healthcare regulations.





Through its convenient California location, 
Development of a small molecule product.
AMGEN has the opportunity to in-license and out-license new products.
Aging affects AMGEN because many drugs and cures, such as arthritis and  cancers, 
are produced for the older population
Expanded product portfolio with Immunex products.
Kineret has $8 billion potential market by 2005.




Patenting and Licensing Battle
Uncertainty of FDA Approval: Approval of ARANESP is delayed, resulting in lower 
near-term revenue and EPS
Development of a less expensive alternative to Epogen or Neupogen by a competitor
Strong influence of insurance companies in the health industry. Any change on policies 
greatly influence the revenues and profit of biotech firms 
Government Policies: Medicare reimbursement of ARANESP and Epogen
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The fundamentals of competitive strategy
The fundamental unit of  competitive strategic 
analysis is the industry
Company economic performance results from two 
distinct causes:











- Rules of Competition
- Sources of Competitive
Advantage
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Source: Med. Adv News, 2002, vol. 21 (7); PhRMA 2001
R & D Investment
All drug PhRMA $38.01
members
Pfizer $  4.44
GlaxoSmithKline $  3.84
Aventis $  3.20
Johnson & Johnson $  2.93
Astra Zeneca $  2.89
Novartis $  2.70
Pharmacia $  2.75
Merck $  2.34
Roche $  2.34
Bayer $  2.19
Source Med. Adv News 2002, Vol 21
Pharmaceutical (20% of sales)
Industry (2000) Billions $
1,200+ biotechnology >$9,000
companies
Amgen $   865
Genentech $   526
Millennium $   400
Chiron $   344
Biogen $   315
Serono $   308
Gilead $   186
Genzyme $   169
Human Genome Sciences $   146
Biotechnology (75% of sales)
Companies (2001) Millions $
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AMGEN`s Competitive Analysis
Key Success Factors for Competitive Advantage: good 
scientists, strong R&D investment, blockbuster drugs, good product 
and innovation process, skills in developing deals to get funding.
Contingencies: technological uncertainty and research success, 
FDA approval, patent protection and being first (second place does 
not count), market size, alternative drugs, legal environment, HMO 
growth/reimbursement issues.
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Reference: Michael Porter, Competitive Strategy, Free Press,1980
Porter's 5 Forces
AMGEN`s Competitive Analysis
Barriers for new biotech companies:
High  cost of R&D
Increasing technology cost (machinery and devices)
High annual salaries for scientist
Long waiting for FDA approval
Access to distribution channels
Suppliers regulated by FDA
AMGEN produces final product and 
also buy from suppliers
Manufacture drugs to sell big companies 





Infergen:  Intron-A (Schering-Plough  market leader
in Hepatit C
ARANESP – Procrin Johnson & Johnson
Epogen and NESP: (Erythropoitein TKT and
Hoechst Marrion Russel) for blood cell production
Leptin (obesity drug): Millenium pharmaceuticals, Roche, 
Neurogen Inc. Pfizer, Genentech,Merck, Novartis Centococor Inc 
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AMGEN`s Competitive Analysis
AMGEN`s Competitors in Each Disease Area and Threat of Substitutes
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Obesity ($33 billion 
annualy)
Rheumotoid  






Hepatitis C INFERGEN Schering-Plough, 
Biogen
LEPTIN Millenium Pharm. Merck
Progenitor Inc, Novartis, 
What is AMGEN`s Competition Strategy ?
“R&D is the l i f e b l o o d of any therapeutics 
endeavor, but it’s much more than that at Amgen
It goes to the very core of our identity.
Our Success comes from one simple-fact- we 

























“Science Push & Patient Pull” Strategy
Successful biotechnology firms live on the innovation edge, AMGEN has very 
strong scientific knowledge and the company established its competitive 
innovation strategy based upon strong scientific knowledge which comes from 
R&D.
Conventional wisdom says listen to the market. Most pharmaceuticals 
companies, and quite a few biotech ones as well, are basically market-driven. 
AMGEN heard things differently. Rather than start with the disease and work 
back to the science, AMGEN assumed that the opposite strategy is superior–that 
companies should take brilliant science and find a unique use for it. 
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Managing Technology with AMGEN`s Formula
Creating   innovation and new technologies based on  strong scientific knowledge 
Invest in R&D at an industry leading percentage of sales.
Aggressively build and advance the product pipeline.( by 2005 which will enable the 
company to participate in new markets with an estimated value of $13 billion )
Attract and retain the best people (managers and scientist).
Being very active in both licensing new technologies and establishing various forms of
collaboration and partnership. 
Balance short term earnings with investment for long-term growth.
AMGEN conducts in-house development of the technologies it sees as being very
important to the company’s future. 
Research collaboration with universities.
Reference: Amgen Outlines Rapid Growth Strategies, Chemical Market Reporter, Life Sciences November 13, 2000 EMGT 520- December-2002
Conclusion/Lessons Learned
The advantage of technology leadership is the opportunity to move fist and 
profit first before competitors.
Both proactive and reactive product strategies provide a business with a 
healthy investment portfolio and can create a successful competitive position.
Amgen’s competitiveness and success depends on superior scientific 
innovation, integrity, and continuous improvement in all aspects of business 
through the application of the scientific method.
Cash flow products in science-based industry are key factors to business 
survival in a long term.
Aggressive R&D and continuous product & process improvement will assure 
future profit.
Alliances can bring fast and achievable capabilities as well as profits that a 
company cannot deliver in a timely manner.
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